Evidence map›Paper›PMID 42483406›Full record

ReviewResearch (Washington, D.C.)2026

Revealing G4 Structures as Drug Targets: Exploring the Potential of Novel Therapeutic Agents.

Ying Che, Yi Peng, Xiaolong Pan, Xiaoyun Hu, Yating Zhao, Yingqi Zhao, Caizhi Tian, Ming Yuan, Yuhang Yin, Rongquan Gan and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ying CheDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Yi PengDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Xiaolong PanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Xiaoyun HuLiaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Yating ZhaoDepartment of Breast Surgery, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, P. R. China.
Yingqi ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Caizhi TianDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Ming YuanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Yuhang YinDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Rongquan GanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Yang LiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Zhanlei PeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Shiyin LiuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Zijian LiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Haobo DongDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Yue TanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Guogui SunDepartment of Chemoradiation, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, P. R. China.
Huizhe WuLiaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning, P. R. China.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, P. R. China.ORCID https://orcid.org/0000-0002-0404-7098

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-quadruplex (G4) structures represent noncanonical secondary formations found in DNA and RNA. Recent research reveals that G4s are abnormally enriched in various cancers, with closely linked to malignancy, metastatic potential, and prognosis. These structures have emerged as promising biomarkers for cancer with notable clinical relevance. Concurrently, investigations into compounds that selectively recognize DNA or RNA G4s as potential anticancer agents offer new avenues for early cancer diagnosis and therapeutic strategies. This review systematically analyzes the chemical structural characteristics, structure-activity relationships, anticancer effects, and mechanisms of G4-targeting molecules in cancer treatment. Additionally, it summarizes novel nucleic acid-based drugs targeting G4 structures, providing valuable insights for the future development of more specific and effective G4-targeted therapeutic agents.

Identifiers

PMID42483406
PMCPMC13385540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.